MedSource establishes preferred provider relationship with Datatrial for e-clinical software nowEDC
HOUSTON, TX. -
MedSource
announced today that it has selected Datatrial's nowEDC™platform as its e-clinical software solution of choice. This latest decision demonstrates MedSource's commitment to provide the best possible value to their clients by offering a state-of-the-art electronic data capture (EDC) solution, nowEDC. The preferred relationship establishes nowEDC as the EDC platform of choice in exchange for preferred pricing for MedSource's full-service clients. "nowEDC has long been a preferred EDC platform by our clients and our staff," said MedSource president and CEO, Eric Lund. "The real-time dynamic reporting capabilities are a significant advantage for our biotech clients and any client who wants immediate access to their data, and who desires the ability to customize reports whenever they choose. It is a platform that provides more accuracy and flexibility than anything we have worked with in the industry. We are excited to offer nowEDC as a solution to our clients and expand our relationship with Datatrial."
Key Advantages of nowEDC software:
"We are excited that MedSource has chosen nowEDC as their EDC software of choice," said Datatrial CEO Emma Banks. "We have been a partner with MedSource for over a decade now and this decision further strengthens our relationship for future growth. We look forward to continuing to serve MedSource and their clients with our best in class nowEDC software and e-clinical and data solutions."
About MedSource
MedSource is recognized as an award winning, full-service clinical research organization (CRO) focusing on complex study designs and complex diseases with a particular expertise in oncology and central nervous system disorders. MedSource began as a specialized clinical monitoring group and has consistently expanded to add services and staff to increase the value we can deliver to our clients. With offices throughout North America, our focus on quality, consistency and transparency has been foundational to our growth.
About nowEDC
The nowEDC system provides data capture, verification and validation, query management, data extract, IWRS and real-time reporting in one integrated system. nowEDC is easy-to-use, fully validated and is highly configurable. The flexible aspects of nowEDC also make it a natural fit for handling both complex trial designs as well as adaptive clinical trials.
About Datatrial
Datatrial is a clinical biometrics and technology organization specializing in complete study delivery. We offer a full range of services including Data Management, Statistics and Medical Writing. With headquarters in Newcastle upon Tyne, UK and offices in Boston MA and BioHub at Alderley Park, UK we are very able to support global clinical development programs. Since 1999, we have been serving the pharmaceutical community through our commitment to service and quality in every aspect of the work that we do. With involvement in over 300 clinical trials, across 25 therapeutic areas and with extensive oncology experience we will work with you to develop a study plan that best fits your needs.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.